PittsburghV1, PascalFrancis, Corpus, bibRecord, 000B01

Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study

Identifieur interne : 000B01 ( PascalFrancis/Corpus ); précédent : 000B00; suivant : 000B02

Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study

Auteurs : Valerie K. Wilson ; Denise K. Houston ; Laurel Kilpatrick ; James Lovato ; Kristine Yaffe ; Jane A. Cauley ; Tamara B. Harris ; Eleanor M. Simonsick ; Hilsa N. Ayonayon ; Stephen B. Kritchevsky ; Kaycee M. Sink

Source :

Journal of the American Geriatrics Society [ 0002-8614 ] ; 2014.

RBID : Pascal:14-0138050

Descripteurs français

Pascal (Inist)
- Vitamine D, Cholécalciférol(25-hydroxy), Cognition, Personne âgée, Santé publique, Vieillissement, Sénescence, Composition corporelle, Mémoire, Gériatrie, Gérontologie.

English descriptors

KwdEn :
- Ageing, Body composition, Cholecalciferol(25-hydroxy), Cognition, Elderly, Geriatrics, Gerontology, Memory, Public health, Senescence, Vitamin D.

Abstract

OBJECTIVES: To examine the relationship between 25-hydroxyvitamin D (25(OH)D) levels and cognitive performance over time in older adults in the Health, Aging and Body Composition (Health ABC) Study. DESIGN: Prospective cohort study. SETTING: Community-dwelling participants in Pittsburgh, Pennsylvania, and Memphis, Tennessee. PARTICIPANTS: Well-functioning adults aged 70 to 79 at baseline with serum 25(OH)D measured at the 12-month follow-up visit and cognitive function measured at baseline and 4-year follow-up visit (N = 2,777). MEASUREMENTS: Vitamin D status was categorized as 25(OH)D levels of less than 20.0 ng/mL, 20.0 to 29.9 ng/mL, or 30.0 ng/mL or greater. Cognition was measured using the modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST). Linear regression models adjusting for multiple covariates, including age, education, sex, race, site, season, physical activity, and comorbidities, were used in the analysis. RESULTS: Sixty-eight percent of participants had 25(OH)D levels of less than 30.0 ng/mL. Lower 25(OH)D levels were associated with lower baseline cognitive scores on the 3MS (adjusted mean 89.9, 95% confidence interval (CI) = 89.4-90.4 for <20.0 ng/mL; adjusted mean 90.8, 95% CI = 90.4-91.3 for 20.0-29.9 ng/mL; adjusted mean 90.6, 95% CI - 90.2-91.1 for ≥30.0 ng/mL; P trend = .02) and the DSST (adjusted mean 35.2, 95% CI = 34.5-36.0 for <20.0 ng/mL; adjusted mean 35.9, 95% CI = 35.2-36.6 for 20.0-29.9 ng/mL; adjusted mean 37.0, 95% CI = 36.3-37.8 for ≥30.0 ng/mL; P trend = .01). Participants with low 25(OH)D levels had greater declines in 3MS scores over 4 years than those with higher levels (least square mean change -1.0, 95% CI = -1.5 to -0.6 for <20.0 ng/mL; least square mean change -0.8, 95% CI = -1.2 to -0.3 for 20.0-29.9 ng/ mL; least square mean change -0.2, 95% CI = -0.7 to 0.2 for ≥30.0 ng/mL; P = .05). There was no significant difference in DSST decline according to 25(OH)D level. CONCLUSION: Low 25(OH)D levels were associated with worse global cognitive function and greater decline over time according to the 3MS. Intervention trials are needed to determine whether vitamin D supplementation can reduce cognitive decline.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0002-8614`
A03		`1`		`@0 J. Am. Geriatr. Soc.`
A05				`@2 62`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study`
A11	`01`	`1`		`@1 WILSON (Valerie K.)`
A11	`02`	`1`		`@1 HOUSTON (Denise K.)`
A11	`03`	`1`		`@1 KILPATRICK (Laurel)`
A11	`04`	`1`		`@1 LOVATO (James)`
A11	`05`	`1`		`@1 YAFFE (Kristine)`
A11	`06`	`1`		`@1 CAULEY (Jane A.)`
A11	`07`	`1`		`@1 HARRIS (Tamara B.)`
A11	`08`	`1`		`@1 SIMONSICK (Eleanor M.)`
A11	`09`	`1`		`@1 AYONAYON (Hilsa N.)`
A11	`10`	`1`		`@1 KRITCHEVSKY (Stephen B.)`
A11	`11`	`1`		`@1 SINK (Kaycee M.)`
A14	`01`			`@1 Department of Internal Medicine, Wake Forest School of Medicine @2 Winston Salem, North Carolina @3 USA @Z 1 aut. @Z 2 aut. @Z 10 aut. @Z 11 aut.`
A14	`02`			`@1 Department of Internal Medicine, University of Alabama at Birmingham @2 Birmingham, Alabama @3 USA @Z 3 aut.`
A14	`03`			`@1 Department of Biostatistics, Wake Forest School of Medicine @2 Winston Salem, North Carolina @3 USA @Z 4 aut.`
A14	`04`			`@1 Department of Psychiatry, University of California at San Francisco @2 San Francisco, California @3 USA @Z 5 aut.`
A14	`05`			`@1 Department of Neurology, University of California at San Francisco @2 San Francisco, California @3 USA @Z 5 aut.`
A14	`06`			`@1 Department of Epidemiology and Biostatistics, University of California at San Francisco @2 San Francisco, California @3 USA @Z 5 aut. @Z 9 aut.`
A14	`07`			`@1 Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh @2 Pittsburgh, Pennsylvania @3 USA @Z 6 aut.`
A14	`08`			`@1 Intramural Research Program, National Institute on Aging @2 Bethesda, Maryland @3 USA @Z 7 aut.`
A14	`09`			`@1 Clinical Research Branch, National Institute on Aging @2 Baltimore, Maryland @3 USA @Z 8 aut.`
A17	`01`	`1`		`@1 Health, Aging and Body Composition Study @3 USA`
A20				`@1 636-641`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 8328 @5 354000503259360060`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 14-0138050`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of the American Geriatrics Society`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 OBJECTIVES: To examine the relationship between 25-hydroxyvitamin D (25(OH)D) levels and cognitive performance over time in older adults in the Health, Aging and Body Composition (Health ABC) Study. DESIGN: Prospective cohort study. SETTING: Community-dwelling participants in Pittsburgh, Pennsylvania, and Memphis, Tennessee. PARTICIPANTS: Well-functioning adults aged 70 to 79 at baseline with serum 25(OH)D measured at the 12-month follow-up visit and cognitive function measured at baseline and 4-year follow-up visit (N = 2,777). MEASUREMENTS: Vitamin D status was categorized as 25(OH)D levels of less than 20.0 ng/mL, 20.0 to 29.9 ng/mL, or 30.0 ng/mL or greater. Cognition was measured using the modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST). Linear regression models adjusting for multiple covariates, including age, education, sex, race, site, season, physical activity, and comorbidities, were used in the analysis. RESULTS: Sixty-eight percent of participants had 25(OH)D levels of less than 30.0 ng/mL. Lower 25(OH)D levels were associated with lower baseline cognitive scores on the 3MS (adjusted mean 89.9, 95% confidence interval (CI) = 89.4-90.4 for <20.0 ng/mL; adjusted mean 90.8, 95% CI = 90.4-91.3 for 20.0-29.9 ng/mL; adjusted mean 90.6, 95% CI - 90.2-91.1 for ≥30.0 ng/mL; P trend = .02) and the DSST (adjusted mean 35.2, 95% CI = 34.5-36.0 for <20.0 ng/mL; adjusted mean 35.9, 95% CI = 35.2-36.6 for 20.0-29.9 ng/mL; adjusted mean 37.0, 95% CI = 36.3-37.8 for ≥30.0 ng/mL; P trend = .01). Participants with low 25(OH)D levels had greater declines in 3MS scores over 4 years than those with higher levels (least square mean change -1.0, 95% CI = -1.5 to -0.6 for <20.0 ng/mL; least square mean change -0.8, 95% CI = -1.2 to -0.3 for 20.0-29.9 ng/ mL; least square mean change -0.2, 95% CI = -0.7 to 0.2 for ≥30.0 ng/mL; P = .05). There was no significant difference in DSST decline according to 25(OH)D level. CONCLUSION: Low 25(OH)D levels were associated with worse global cognitive function and greater decline over time according to the 3MS. Intervention trials are needed to determine whether vitamin D supplementation can reduce cognitive decline.
C02	`01`	`X`		`@0 002B01`
C02	`02`	`X`		`@0 002B30A11`
C03	`01`	`X`	`FRE`	`@0 Vitamine D @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Vitamin D @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Vitamina D @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Cholécalciférol(25-hydroxy) @2 NK @5 02`
C03	`02`	`X`	`ENG`	`@0 Cholecalciferol(25-hydroxy) @2 NK @5 02`
C03	`02`	`X`	`SPA`	`@0 Colecalciferol(25-hidroxi) @2 NK @5 02`
C03	`03`	`X`	`FRE`	`@0 Cognition @5 03`
C03	`03`	`X`	`ENG`	`@0 Cognition @5 03`
C03	`03`	`X`	`SPA`	`@0 Cognición @5 03`
C03	`04`	`X`	`FRE`	`@0 Personne âgée @5 05`
C03	`04`	`X`	`ENG`	`@0 Elderly @5 05`
C03	`04`	`X`	`SPA`	`@0 Anciano @5 05`
C03	`05`	`X`	`FRE`	`@0 Santé publique @5 06`
C03	`05`	`X`	`ENG`	`@0 Public health @5 06`
C03	`05`	`X`	`SPA`	`@0 Salud pública @5 06`
C03	`06`	`X`	`FRE`	`@0 Vieillissement @5 08`
C03	`06`	`X`	`ENG`	`@0 Ageing @5 08`
C03	`06`	`X`	`SPA`	`@0 Envejecimiento @5 08`
C03	`07`	`X`	`FRE`	`@0 Sénescence @5 09`
C03	`07`	`X`	`ENG`	`@0 Senescence @5 09`
C03	`07`	`X`	`SPA`	`@0 Senescencia @5 09`
C03	`08`	`X`	`FRE`	`@0 Composition corporelle @5 11`
C03	`08`	`X`	`ENG`	`@0 Body composition @5 11`
C03	`08`	`X`	`SPA`	`@0 Composicíon corporal @5 11`
C03	`09`	`X`	`FRE`	`@0 Mémoire @5 12`
C03	`09`	`X`	`ENG`	`@0 Memory @5 12`
C03	`09`	`X`	`SPA`	`@0 Memoria @5 12`
C03	`10`	`X`	`FRE`	`@0 Gériatrie @5 17`
C03	`10`	`X`	`ENG`	`@0 Geriatrics @5 17`
C03	`10`	`X`	`SPA`	`@0 Geriatría @5 17`
C03	`11`	`X`	`FRE`	`@0 Gérontologie @5 18`
C03	`11`	`X`	`ENG`	`@0 Gerontology @5 18`
C03	`11`	`X`	`SPA`	`@0 Gerontología @5 18`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Hormone stéroïde @5 37`
C07	`02`	`X`	`ENG`	`@0 Steroid hormone @5 37`
C07	`02`	`X`	`SPA`	`@0 Hormona esteroide @5 37`
N21				`@1 174`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0138050 INIST
ET :	Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study
AU :	WILSON (Valerie K.); HOUSTON (Denise K.); KILPATRICK (Laurel); LOVATO (James); YAFFE (Kristine); CAULEY (Jane A.); HARRIS (Tamara B.); SIMONSICK (Eleanor M.); AYONAYON (Hilsa N.); KRITCHEVSKY (Stephen B.); SINK (Kaycee M.)
AF :	Department of Internal Medicine, Wake Forest School of Medicine/Winston Salem, North Carolina/Etats-Unis (1 aut., 2 aut., 10 aut., 11 aut.); Department of Internal Medicine, University of Alabama at Birmingham/Birmingham, Alabama/Etats-Unis (3 aut.); Department of Biostatistics, Wake Forest School of Medicine/Winston Salem, North Carolina/Etats-Unis (4 aut.); Department of Psychiatry, University of California at San Francisco/San Francisco, California/Etats-Unis (5 aut.); Department of Neurology, University of California at San Francisco/San Francisco, California/Etats-Unis (5 aut.); Department of Epidemiology and Biostatistics, University of California at San Francisco/San Francisco, California/Etats-Unis (5 aut., 9 aut.); Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh/Pittsburgh, Pennsylvania/Etats-Unis (6 aut.); Intramural Research Program, National Institute on Aging/Bethesda, Maryland/Etats-Unis (7 aut.); Clinical Research Branch, National Institute on Aging/Baltimore, Maryland/Etats-Unis (8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of the American Geriatrics Society; ISSN 0002-8614; Etats-Unis; Da. 2014; Vol. 62; No. 4; Pp. 636-641; Bibl. 24 ref.
LA :	Anglais
EA :	OBJECTIVES: To examine the relationship between 25-hydroxyvitamin D (25(OH)D) levels and cognitive performance over time in older adults in the Health, Aging and Body Composition (Health ABC) Study. DESIGN: Prospective cohort study. SETTING: Community-dwelling participants in Pittsburgh, Pennsylvania, and Memphis, Tennessee. PARTICIPANTS: Well-functioning adults aged 70 to 79 at baseline with serum 25(OH)D measured at the 12-month follow-up visit and cognitive function measured at baseline and 4-year follow-up visit (N = 2,777). MEASUREMENTS: Vitamin D status was categorized as 25(OH)D levels of less than 20.0 ng/mL, 20.0 to 29.9 ng/mL, or 30.0 ng/mL or greater. Cognition was measured using the modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST). Linear regression models adjusting for multiple covariates, including age, education, sex, race, site, season, physical activity, and comorbidities, were used in the analysis. RESULTS: Sixty-eight percent of participants had 25(OH)D levels of less than 30.0 ng/mL. Lower 25(OH)D levels were associated with lower baseline cognitive scores on the 3MS (adjusted mean 89.9, 95% confidence interval (CI) = 89.4-90.4 for <20.0 ng/mL; adjusted mean 90.8, 95% CI = 90.4-91.3 for 20.0-29.9 ng/mL; adjusted mean 90.6, 95% CI - 90.2-91.1 for ≥30.0 ng/mL; P trend = .02) and the DSST (adjusted mean 35.2, 95% CI = 34.5-36.0 for <20.0 ng/mL; adjusted mean 35.9, 95% CI = 35.2-36.6 for 20.0-29.9 ng/mL; adjusted mean 37.0, 95% CI = 36.3-37.8 for ≥30.0 ng/mL; P trend = .01). Participants with low 25(OH)D levels had greater declines in 3MS scores over 4 years than those with higher levels (least square mean change -1.0, 95% CI = -1.5 to -0.6 for <20.0 ng/mL; least square mean change -0.8, 95% CI = -1.2 to -0.3 for 20.0-29.9 ng/ mL; least square mean change -0.2, 95% CI = -0.7 to 0.2 for ≥30.0 ng/mL; P = .05). There was no significant difference in DSST decline according to 25(OH)D level. CONCLUSION: Low 25(OH)D levels were associated with worse global cognitive function and greater decline over time according to the 3MS. Intervention trials are needed to determine whether vitamin D supplementation can reduce cognitive decline.
CC :	002B01; 002B30A11
FD :	Vitamine D; Cholécalciférol(25-hydroxy); Cognition; Personne âgée; Santé publique; Vieillissement; Sénescence; Composition corporelle; Mémoire; Gériatrie; Gérontologie
FG :	Homme; Hormone stéroïde
ED :	Vitamin D; Cholecalciferol(25-hydroxy); Cognition; Elderly; Public health; Ageing; Senescence; Body composition; Memory; Geriatrics; Gerontology
EG :	Human; Steroid hormone
SD :	Vitamina D; Colecalciferol(25-hidroxi); Cognición; Anciano; Salud pública; Envejecimiento; Senescencia; Composicíon corporal; Memoria; Geriatría; Gerontología
LO :	INIST-8328.354000503259360060
ID :	14-0138050

Links to Exploration step

Pascal:14-0138050

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study</title>
<author><name sortKey="Wilson, Valerie K" sort="Wilson, Valerie K" uniqKey="Wilson V" first="Valerie K." last="Wilson">Valerie K. Wilson</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houston, Denise K" sort="Houston, Denise K" uniqKey="Houston D" first="Denise K." last="Houston">Denise K. Houston</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kilpatrick, Laurel" sort="Kilpatrick, Laurel" uniqKey="Kilpatrick L" first="Laurel" last="Kilpatrick">Laurel Kilpatrick</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Internal Medicine, University of Alabama at Birmingham</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lovato, James" sort="Lovato, James" uniqKey="Lovato J" first="James" last="Lovato">James Lovato</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Biostatistics, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yaffe, Kristine" sort="Yaffe, Kristine" uniqKey="Yaffe K" first="Kristine" last="Yaffe">Kristine Yaffe</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Psychiatry, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Department of Epidemiology and Biostatistics, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cauley, Jane A" sort="Cauley, Jane A" uniqKey="Cauley J" first="Jane A." last="Cauley">Jane A. Cauley</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harris, Tamara B" sort="Harris, Tamara B" uniqKey="Harris T" first="Tamara B." last="Harris">Tamara B. Harris</name>
<affiliation><inist:fA14 i1="08"><s1>Intramural Research Program, National Institute on Aging</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Simonsick, Eleanor M" sort="Simonsick, Eleanor M" uniqKey="Simonsick E" first="Eleanor M." last="Simonsick">Eleanor M. Simonsick</name>
<affiliation><inist:fA14 i1="09"><s1>Clinical Research Branch, National Institute on Aging</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ayonayon, Hilsa N" sort="Ayonayon, Hilsa N" uniqKey="Ayonayon H" first="Hilsa N." last="Ayonayon">Hilsa N. Ayonayon</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Epidemiology and Biostatistics, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kritchevsky, Stephen B" sort="Kritchevsky, Stephen B" uniqKey="Kritchevsky S" first="Stephen B." last="Kritchevsky">Stephen B. Kritchevsky</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sink, Kaycee M" sort="Sink, Kaycee M" uniqKey="Sink K" first="Kaycee M." last="Sink">Kaycee M. Sink</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0138050</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0138050 INIST</idno>
<idno type="RBID">Pascal:14-0138050</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B01</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study</title>
<author><name sortKey="Wilson, Valerie K" sort="Wilson, Valerie K" uniqKey="Wilson V" first="Valerie K." last="Wilson">Valerie K. Wilson</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houston, Denise K" sort="Houston, Denise K" uniqKey="Houston D" first="Denise K." last="Houston">Denise K. Houston</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kilpatrick, Laurel" sort="Kilpatrick, Laurel" uniqKey="Kilpatrick L" first="Laurel" last="Kilpatrick">Laurel Kilpatrick</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Internal Medicine, University of Alabama at Birmingham</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lovato, James" sort="Lovato, James" uniqKey="Lovato J" first="James" last="Lovato">James Lovato</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Biostatistics, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yaffe, Kristine" sort="Yaffe, Kristine" uniqKey="Yaffe K" first="Kristine" last="Yaffe">Kristine Yaffe</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Psychiatry, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Department of Epidemiology and Biostatistics, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cauley, Jane A" sort="Cauley, Jane A" uniqKey="Cauley J" first="Jane A." last="Cauley">Jane A. Cauley</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harris, Tamara B" sort="Harris, Tamara B" uniqKey="Harris T" first="Tamara B." last="Harris">Tamara B. Harris</name>
<affiliation><inist:fA14 i1="08"><s1>Intramural Research Program, National Institute on Aging</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Simonsick, Eleanor M" sort="Simonsick, Eleanor M" uniqKey="Simonsick E" first="Eleanor M." last="Simonsick">Eleanor M. Simonsick</name>
<affiliation><inist:fA14 i1="09"><s1>Clinical Research Branch, National Institute on Aging</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ayonayon, Hilsa N" sort="Ayonayon, Hilsa N" uniqKey="Ayonayon H" first="Hilsa N." last="Ayonayon">Hilsa N. Ayonayon</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Epidemiology and Biostatistics, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kritchevsky, Stephen B" sort="Kritchevsky, Stephen B" uniqKey="Kritchevsky S" first="Stephen B." last="Kritchevsky">Stephen B. Kritchevsky</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sink, Kaycee M" sort="Sink, Kaycee M" uniqKey="Sink K" first="Kaycee M." last="Sink">Kaycee M. Sink</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of the American Geriatrics Society</title>
<title level="j" type="abbreviated">J. Am. Geriatr. Soc.</title>
<idno type="ISSN">0002-8614</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of the American Geriatrics Society</title>
<title level="j" type="abbreviated">J. Am. Geriatr. Soc.</title>
<idno type="ISSN">0002-8614</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ageing</term>
<term>Body composition</term>
<term>Cholecalciferol(25-hydroxy)</term>
<term>Cognition</term>
<term>Elderly</term>
<term>Geriatrics</term>
<term>Gerontology</term>
<term>Memory</term>
<term>Public health</term>
<term>Senescence</term>
<term>Vitamin D</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Vitamine D</term>
<term>Cholécalciférol(25-hydroxy)</term>
<term>Cognition</term>
<term>Personne âgée</term>
<term>Santé publique</term>
<term>Vieillissement</term>
<term>Sénescence</term>
<term>Composition corporelle</term>
<term>Mémoire</term>
<term>Gériatrie</term>
<term>Gérontologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">OBJECTIVES: To examine the relationship between 25-hydroxyvitamin D (25(OH)D) levels and cognitive performance over time in older adults in the Health, Aging and Body Composition (Health ABC) Study. DESIGN: Prospective cohort study. SETTING: Community-dwelling participants in Pittsburgh, Pennsylvania, and Memphis, Tennessee. PARTICIPANTS: Well-functioning adults aged 70 to 79 at baseline with serum 25(OH)D measured at the 12-month follow-up visit and cognitive function measured at baseline and 4-year follow-up visit (N = 2,777). MEASUREMENTS: Vitamin D status was categorized as 25(OH)D levels of less than 20.0 ng/mL, 20.0 to 29.9 ng/mL, or 30.0 ng/mL or greater. Cognition was measured using the modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST). Linear regression models adjusting for multiple covariates, including age, education, sex, race, site, season, physical activity, and comorbidities, were used in the analysis. RESULTS: Sixty-eight percent of participants had 25(OH)D levels of less than 30.0 ng/mL. Lower 25(OH)D levels were associated with lower baseline cognitive scores on the 3MS (adjusted mean 89.9, 95% confidence interval (CI) = 89.4-90.4 for <20.0 ng/mL; adjusted mean 90.8, 95% CI = 90.4-91.3 for 20.0-29.9 ng/mL; adjusted mean 90.6, 95% CI - 90.2-91.1 for ≥30.0 ng/mL; P trend = .02) and the DSST (adjusted mean 35.2, 95% CI = 34.5-36.0 for <20.0 ng/mL; adjusted mean 35.9, 95% CI = 35.2-36.6 for 20.0-29.9 ng/mL; adjusted mean 37.0, 95% CI = 36.3-37.8 for ≥30.0 ng/mL; P trend = .01). Participants with low 25(OH)D levels had greater declines in 3MS scores over 4 years than those with higher levels (least square mean change -1.0, 95% CI = -1.5 to -0.6 for <20.0 ng/mL; least square mean change -0.8, 95% CI = -1.2 to -0.3 for 20.0-29.9 ng/ mL; least square mean change -0.2, 95% CI = -0.7 to 0.2 for ≥30.0 ng/mL; P = .05). There was no significant difference in DSST decline according to 25(OH)D level. CONCLUSION: Low 25(OH)D levels were associated with worse global cognitive function and greater decline over time according to the 3MS. Intervention trials are needed to determine whether vitamin D supplementation can reduce cognitive decline.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0002-8614</s0>
</fA01>
<fA03 i2="1"><s0>J. Am. Geriatr. Soc.</s0>
</fA03>
<fA05><s2>62</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WILSON (Valerie K.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HOUSTON (Denise K.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KILPATRICK (Laurel)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LOVATO (James)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>YAFFE (Kristine)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CAULEY (Jane A.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HARRIS (Tamara B.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SIMONSICK (Eleanor M.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>AYONAYON (Hilsa N.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>KRITCHEVSKY (Stephen B.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>SINK (Kaycee M.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Internal Medicine, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Internal Medicine, University of Alabama at Birmingham</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Biostatistics, Wake Forest School of Medicine</s1>
<s2>Winston Salem, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Psychiatry, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Epidemiology and Biostatistics, University of California at San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Intramural Research Program, National Institute on Aging</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Clinical Research Branch, National Institute on Aging</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>Health, Aging and Body Composition Study</s1>
<s3>USA</s3>
</fA17>
<fA20><s1>636-641</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>8328</s2>
<s5>354000503259360060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0138050</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of the American Geriatrics Society</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>OBJECTIVES: To examine the relationship between 25-hydroxyvitamin D (25(OH)D) levels and cognitive performance over time in older adults in the Health, Aging and Body Composition (Health ABC) Study. DESIGN: Prospective cohort study. SETTING: Community-dwelling participants in Pittsburgh, Pennsylvania, and Memphis, Tennessee. PARTICIPANTS: Well-functioning adults aged 70 to 79 at baseline with serum 25(OH)D measured at the 12-month follow-up visit and cognitive function measured at baseline and 4-year follow-up visit (N = 2,777). MEASUREMENTS: Vitamin D status was categorized as 25(OH)D levels of less than 20.0 ng/mL, 20.0 to 29.9 ng/mL, or 30.0 ng/mL or greater. Cognition was measured using the modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST). Linear regression models adjusting for multiple covariates, including age, education, sex, race, site, season, physical activity, and comorbidities, were used in the analysis. RESULTS: Sixty-eight percent of participants had 25(OH)D levels of less than 30.0 ng/mL. Lower 25(OH)D levels were associated with lower baseline cognitive scores on the 3MS (adjusted mean 89.9, 95% confidence interval (CI) = 89.4-90.4 for <20.0 ng/mL; adjusted mean 90.8, 95% CI = 90.4-91.3 for 20.0-29.9 ng/mL; adjusted mean 90.6, 95% CI - 90.2-91.1 for ≥30.0 ng/mL; P trend = .02) and the DSST (adjusted mean 35.2, 95% CI = 34.5-36.0 for <20.0 ng/mL; adjusted mean 35.9, 95% CI = 35.2-36.6 for 20.0-29.9 ng/mL; adjusted mean 37.0, 95% CI = 36.3-37.8 for ≥30.0 ng/mL; P trend = .01). Participants with low 25(OH)D levels had greater declines in 3MS scores over 4 years than those with higher levels (least square mean change -1.0, 95% CI = -1.5 to -0.6 for <20.0 ng/mL; least square mean change -0.8, 95% CI = -1.2 to -0.3 for 20.0-29.9 ng/ mL; least square mean change -0.2, 95% CI = -0.7 to 0.2 for ≥30.0 ng/mL; P = .05). There was no significant difference in DSST decline according to 25(OH)D level. CONCLUSION: Low 25(OH)D levels were associated with worse global cognitive function and greater decline over time according to the 3MS. Intervention trials are needed to determine whether vitamin D supplementation can reduce cognitive decline.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B30A11</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Vitamine D</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Vitamin D</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Vitamina D</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cholécalciférol(25-hydroxy)</s0>
<s2>NK</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cholecalciferol(25-hydroxy)</s0>
<s2>NK</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Colecalciferol(25-hidroxi)</s0>
<s2>NK</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Cognition</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Cognition</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Cognición</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Elderly</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Anciano</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Public health</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Vieillissement</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Ageing</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Envejecimiento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Sénescence</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Senescence</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Senescencia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Composition corporelle</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Body composition</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Composicíon corporal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Mémoire</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Memory</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Memoria</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Gériatrie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Geriatrics</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Geriatría</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Gérontologie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Gerontology</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Gerontología</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Hormone stéroïde</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Steroid hormone</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Hormona esteroide</s0>
<s5>37</s5>
</fC07>
<fN21><s1>174</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0138050 INIST</NO>
<ET>Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study</ET>
<AU>WILSON (Valerie K.); HOUSTON (Denise K.); KILPATRICK (Laurel); LOVATO (James); YAFFE (Kristine); CAULEY (Jane A.); HARRIS (Tamara B.); SIMONSICK (Eleanor M.); AYONAYON (Hilsa N.); KRITCHEVSKY (Stephen B.); SINK (Kaycee M.)</AU>
<AF>Department of Internal Medicine, Wake Forest School of Medicine/Winston Salem, North Carolina/Etats-Unis (1 aut., 2 aut., 10 aut., 11 aut.); Department of Internal Medicine, University of Alabama at Birmingham/Birmingham, Alabama/Etats-Unis (3 aut.); Department of Biostatistics, Wake Forest School of Medicine/Winston Salem, North Carolina/Etats-Unis (4 aut.); Department of Psychiatry, University of California at San Francisco/San Francisco, California/Etats-Unis (5 aut.); Department of Neurology, University of California at San Francisco/San Francisco, California/Etats-Unis (5 aut.); Department of Epidemiology and Biostatistics, University of California at San Francisco/San Francisco, California/Etats-Unis (5 aut., 9 aut.); Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh/Pittsburgh, Pennsylvania/Etats-Unis (6 aut.); Intramural Research Program, National Institute on Aging/Bethesda, Maryland/Etats-Unis (7 aut.); Clinical Research Branch, National Institute on Aging/Baltimore, Maryland/Etats-Unis (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of the American Geriatrics Society; ISSN 0002-8614; Etats-Unis; Da. 2014; Vol. 62; No. 4; Pp. 636-641; Bibl. 24 ref.</SO>
<LA>Anglais</LA>
<EA>OBJECTIVES: To examine the relationship between 25-hydroxyvitamin D (25(OH)D) levels and cognitive performance over time in older adults in the Health, Aging and Body Composition (Health ABC) Study. DESIGN: Prospective cohort study. SETTING: Community-dwelling participants in Pittsburgh, Pennsylvania, and Memphis, Tennessee. PARTICIPANTS: Well-functioning adults aged 70 to 79 at baseline with serum 25(OH)D measured at the 12-month follow-up visit and cognitive function measured at baseline and 4-year follow-up visit (N = 2,777). MEASUREMENTS: Vitamin D status was categorized as 25(OH)D levels of less than 20.0 ng/mL, 20.0 to 29.9 ng/mL, or 30.0 ng/mL or greater. Cognition was measured using the modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST). Linear regression models adjusting for multiple covariates, including age, education, sex, race, site, season, physical activity, and comorbidities, were used in the analysis. RESULTS: Sixty-eight percent of participants had 25(OH)D levels of less than 30.0 ng/mL. Lower 25(OH)D levels were associated with lower baseline cognitive scores on the 3MS (adjusted mean 89.9, 95% confidence interval (CI) = 89.4-90.4 for <20.0 ng/mL; adjusted mean 90.8, 95% CI = 90.4-91.3 for 20.0-29.9 ng/mL; adjusted mean 90.6, 95% CI - 90.2-91.1 for ≥30.0 ng/mL; P trend = .02) and the DSST (adjusted mean 35.2, 95% CI = 34.5-36.0 for <20.0 ng/mL; adjusted mean 35.9, 95% CI = 35.2-36.6 for 20.0-29.9 ng/mL; adjusted mean 37.0, 95% CI = 36.3-37.8 for ≥30.0 ng/mL; P trend = .01). Participants with low 25(OH)D levels had greater declines in 3MS scores over 4 years than those with higher levels (least square mean change -1.0, 95% CI = -1.5 to -0.6 for <20.0 ng/mL; least square mean change -0.8, 95% CI = -1.2 to -0.3 for 20.0-29.9 ng/ mL; least square mean change -0.2, 95% CI = -0.7 to 0.2 for ≥30.0 ng/mL; P = .05). There was no significant difference in DSST decline according to 25(OH)D level. CONCLUSION: Low 25(OH)D levels were associated with worse global cognitive function and greater decline over time according to the 3MS. Intervention trials are needed to determine whether vitamin D supplementation can reduce cognitive decline.</EA>
<CC>002B01; 002B30A11</CC>
<FD>Vitamine D; Cholécalciférol(25-hydroxy); Cognition; Personne âgée; Santé publique; Vieillissement; Sénescence; Composition corporelle; Mémoire; Gériatrie; Gérontologie</FD>
<FG>Homme; Hormone stéroïde</FG>
<ED>Vitamin D; Cholecalciferol(25-hydroxy); Cognition; Elderly; Public health; Ageing; Senescence; Body composition; Memory; Geriatrics; Gerontology</ED>
<EG>Human; Steroid hormone</EG>
<SD>Vitamina D; Colecalciferol(25-hidroxi); Cognición; Anciano; Salud pública; Envejecimiento; Senescencia; Composicíon corporal; Memoria; Geriatría; Gerontología</SD>
<LO>INIST-8328.354000503259360060</LO>
<ID>14-0138050</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B01 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B01 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0138050
   |texte=   Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study

Relationship Between 25-Hydroxyvitamin D and Cognitive Function in Older Adults: The Health, Aging and Body Composition Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri